Brief: Quantum Genomics Enters Agreement On Firibastat

Quantum Genomics SA

09/12/2019 17:19

Dec 9 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS AND BIOLAB SANUS PHARMACEUTICAL ENTER
INTO
EXCLUSIVE LICENSING AND COLLABORATION AGREEMENT FOR FIRIBASTAT
IN LATIN AMERICA
    * BIOLAB SANUS PHARMACEUTICAL WILL FUND PART OF THE PHASE
III
STUDY IN DIFFICULT TO TREAT/RESISTANT HYPERTENSION IN LATIN
AMERICA AS PART OF THE OVERALL PIVOTAL PHASE III TRIAL LED BY
QUANTUM GENOMICS
    * QUANTUM GENOMICS WILL RECEIVE UPFRONT AND MILESTONE
PAYMENTS
AMOUNTING UP TO $ 21,2 MILLION
    * QUANTUM GENOMICS WILL ALSO RECEIVE ROYALTIES ON SALES
    * THIS IS THE FIRST REGIONAL PARTNERSHIP FOR QUANTUM
GENOMICS

Source text for Eikon:  ID:nGNX8rXbXv 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))